
Product Name: Recombinant SARS-CoV-2 Papain-Like Protease **Enkilife** Catalog #: PEV2233

Summary

Name	Papain-Like Protease/NSP3
Purity	Greater than 95% as determined by reducing SDS-PAGE
Endotoxin level	Please contact with the lab for this information
Construction	Recombinant 2019-nCoV Papain-like Protease is produced by our E.coli expression system and the target gene encoding Glu1564-Lys1878 is expressed.
Accession #	QHD43415.1
Host	E.coli
Species	SARS-CoV-2
Predicted Molecular Mass	35.8 KDa
Formulation	Supplied as a 0.2 µm filtered solution of 20mM Tris-HCl, 10 mM 2- Mercaptoethanol, 20% Glycerol, pH 7.5.
Shipping	The product is shipped on dry ice/polar packs. Upon receipt, store it immediately at the temperature listed below.
Stability&Storage	Store at \leq -70°C, stable for 6 months after receipt. Store at \leq -70°C, stable for 3 months under sterile conditions after opening. Please minimize freeze-thaw cycles.
Reconstitution	

SDS-PAGE image



Background

Background Replication of severe acute respiratory syndrome (SARS) coronavirus ((SARS-CoV)

requires proteolytic processing of the replicase polyprotein by two viral cysteine proteases, a chymotrypsin-like protease (3CLpro) and a papain-like protease (PLpro). These proteases are important targets for development of antiviral drugs that would inhibit viral replication and reduce mortality associated with outbreaks of SARS-CoV. PLpro is a cysteine protease located within the non-structural protein 3 (NS3) section of the viral polypeptide. PLPro activity is required to process the viral polyprotein into functional, mature subunits; specifically, PLPro cleaves a site at the amino-terminus of the viral replicase region. In addition to its role in viral protein maturation, PLPro possesses a deubiquitinating and delSGylating activity. In vivo, this protease antagonizes innate immunity by inhibiting IRF3-induced production of type I interferons.

Note

For Research Use Only, Not for Diagnostic Use.